Serial xenotransplantation of sorted cancer cells in immunodeficient mice remains the most complex test of cancer stem cell (CSC) phenotype. However, we have demonstrated in various sarcomas that putative CSC surface markers fail to identify CSCs, thereby impeding the isolation of CSCs for subsequent analyses. Here, we utilized serial xenotransplantation of unsorted rhabdomyosarcoma cells in NOD/SCID gamma (NSG) mice as a proof-of-principle platform to investigate the molecular signature of CSCs. Indeed, serial xenotransplantation steadily enriched for rhabdomyosarcoma stem-like cells characterized by enhanced aldehyde dehydrogenase activity and increased colony and sphere formation capacity in vitro. Although the expression of core pluripotency factors (SOX2, OCT4, NANOG) and common CSC markers (CD133, ABCG2, nestin) was maintained over the passages in mice, gene expression profiling revealed gradual changes in several stemness regulators and genes linked with undifferentiated myogenic precursors, e.g., SOX4, PAX3, MIR145, and CDH15. Moreover, we identified the induction of a hybrid epithelial/mesenchymal gene expression signature that was associated with the increase in CSC number. In total, 60 genes related to epithelial or mesenchymal traits were significantly altered upon serial xenotransplantation. In silico survival analysis based on the identified potential stemness-associated genes demonstrated that serial xenotransplantation of unsorted rhabdomyosarcoma cells in NSG mice might be a useful tool for the unbiased enrichment of CSCs and the identification of novel CSC-specific targets. Using this approach, we provide evidence for a recently proposed link between the hybrid epithelial/mesenchymal phenotype and cancer stemness.

1st Department of Pathological Anatomy St Anne's University Hospital and Faculty of Medicine Masaryk University 65691 Brno Czech Republic

Department of Experimental Biology Faculty of Science Masaryk University 61137 Brno Czech Republic

Department of Pediatric Oncology University Hospital Brno and Faculty of Medicine Masaryk University 62500 Brno Czech Republic

International Clinical Research Center St Anne's University Hospital 65691 Brno Czech Republic

Zobrazit více v PubMed

Yang L., Takimoto T., Fujimoto J. Prognostic model for predicting overall survival in children and adolescents with rhabdomyosarcoma. BMC Cancer. 2014;14:654. doi: 10.1186/1471-2407-14-654. PubMed DOI PMC

Winter S., Fasola S., Brisse H., Mosseri V., Orbach D. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy. Pediatr. Blood Cancer. 2015;62:1935–1941. doi: 10.1002/pbc.25622. PubMed DOI

Sana J., Zambo I., Skoda J., Neradil J., Chlapek P., Hermanova M., Mudry P., Vasikova A., Zitterbart K., Hampl A., et al. CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines. Anal. Cell. Pathol. 2011;34:303–318. doi: 10.1155/2011/939457. PubMed DOI PMC

Walter D., Satheesha S., Albrecht P., Bornhauser B.C., D’Alessandro V., Oesch S.M., Rehrauer H., Leuschner I., Koscielniak E., Gengler C., et al. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS ONE. 2011;6:e19506. doi: 10.1371/journal.pone.0019506. PubMed DOI PMC

Skoda J., Nunukova A., Loja T., Zambo I., Neradil J., Mudry P., Zitterbart K., Hermanova M., Hampl A., Sterba J., et al. Cancer stem cell markers in pediatric sarcomas: Sox2 is associated with tumorigenicity in immunodeficient mice. Tumor Biol. 2016;37:9535–9548. doi: 10.1007/s13277-016-4837-0. PubMed DOI

Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., Wahl G.M. Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339–9344. doi: 10.1158/0008-5472.CAN-06-3126. PubMed DOI

Kim W.T., Ryu C.J. Cancer stem cell surface markers on normal stem cells. BMB Rep. 2017;50:285–298. doi: 10.5483/BMBRep.2017.50.6.039. PubMed DOI PMC

Skoda J., Veselska R. Cancer stem cells in sarcomas: Getting to the stemness core. Biochim. Biophys. Acta Gen. Subj. 2018;1862:2134–2139. doi: 10.1016/j.bbagen.2018.07.006. PubMed DOI

Nunukova A., Neradil J., Skoda J., Jaros J., Hampl A., Sterba J., Veselska R. Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines. Int. J. Mol. Med. 2015;36:65–72. doi: 10.3892/ijmm.2015.2210. PubMed DOI PMC

Skoda J., Hermanova M., Loja T., Nemec P., Neradil J., Karasek P., Veselska R. Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma. PLoS ONE. 2016;11 doi: 10.1371/journal.pone.0159255. PubMed DOI PMC

Duex J.E., Owens C., Chauca-Diaz A., Dancik G.M., Vanderlinden L.A., Ghosh D., Leivo M.Z., Hansel D.E., Theodorescu D. Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis. Cancer Res. 2017;77:4858–4867. doi: 10.1158/0008-5472.CAN-17-0367. PubMed DOI PMC

Agliano A., Calvo A., Box C. The challenge of targeting cancer stem cells to halt metastasis. Semin. Cancer Biol. 2017;44:25–42. doi: 10.1016/j.semcancer.2017.03.003. PubMed DOI

Iglesias J.M., Gumuzio J., Martin A.G. Linking Pluripotency Reprogramming and Cancer. Stem Cells Transl. Med. 2017;6:335–339. doi: 10.5966/sctm.2015-0225. PubMed DOI PMC

Malta T.M., Sokolov A., Gentles A.J., Burzykowski T., Poisson L., Weinstein J.N., Kaminska B., Huelsken J., Omberg L., Gevaert O., et al. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 2018;173:338–354. doi: 10.1016/j.cell.2018.03.034. PubMed DOI PMC

Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–115. doi: 10.1038/nature05384. PubMed DOI

Ying M., Liu G., Shimada H., Ding W., May W.A., He Q., Adams G.B., Wu L. Human osteosarcoma CD49f−CD133+ cells: Impaired in osteogenic fate while gain of tumorigenicity. Oncogene. 2013;32:4252–4263. doi: 10.1038/onc.2012.438. PubMed DOI PMC

Golan H., Shukrun R., Caspi R., Vax E., Pode-Shakked N., Goldberg S., Pleniceanu O., Bar-Lev D.D., Mark-Danieli M., Pri-Chen S., et al. In Vivo Expansion of Cancer Stemness Affords Novel Cancer Stem Cell Targets: Malignant Rhabdoid Tumor as an Example. Stem Cell Rep. 2018;11:795–810. doi: 10.1016/j.stemcr.2018.07.010. PubMed DOI PMC

Nakahata K., Uehara S., Nishikawa S., Kawatsu M., Zenitani M., Oue T., Okuyama H. Aldehyde Dehydrogenase 1 (ALDH1) Is a Potential Marker for Cancer Stem Cells in Embryonal Rhabdomyosarcoma. PLoS ONE. 2015;10:e0125454. doi: 10.1371/journal.pone.0125454. PubMed DOI PMC

Tomita H., Tanaka K., Tanaka T., Hara A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. 2016;7:11018–11032. doi: 10.18632/oncotarget.6920. PubMed DOI PMC

George J.T., Jolly M.K., Xu S., Somarelli J.A., Levine H. Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. Cancer Res. 2017;77:6415–6428. doi: 10.1158/0008-5472.CAN-16-3521. PubMed DOI PMC

Groger C.J., Grubinger M., Waldhor T., Vierlinger K., Mikulits W. Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS ONE. 2012;7:e51136. doi: 10.1371/journal.pone.0051136. PubMed DOI PMC

Wachtel M., Schafer B.W. Unpeaceful roles of mutant PAX proteins in cancer. Semin. Cell Dev. Biol. 2015;44:126–134. doi: 10.1016/j.semcdb.2015.09.011. PubMed DOI

Buckingham M. Gene regulatory networks and cell lineages that underlie the formation of skeletal muscle. Proc. Natl. Acad. Sci. USA. 2017;114:5830–5837. doi: 10.1073/pnas.1610605114. PubMed DOI PMC

Xu N., Papagiannakopoulos T., Pan G., Thomson J.A., Kosik K.S. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009;137:647–658. doi: 10.1016/j.cell.2009.02.038. PubMed DOI

Medeiros Tavares Marques J.C., Cornelio D.A., Nogueira Silbiger V., Ducati Luchessi A., de Souza S., Batistuzzo de Medeiros S.R. Identification of new genes associated to senescent and tumorigenic phenotypes in mesenchymal stem cells. Sci. Rep. 2017;7:17837. doi: 10.1038/s41598-017-16224-5. PubMed DOI PMC

Katso R.M., Russell R.B., Ganesan T.S. Functional analysis of H-Ryk, an atypical member of the receptor tyrosine kinase family. Mol. Cell. Biol. 1999;19:6427–6440. doi: 10.1128/MCB.19.9.6427. PubMed DOI PMC

Roy J.P., Halford M.M., Stacker S.A. The biochemistry, signalling and disease relevance of RYK and other WNT-binding receptor tyrosine kinases. Growth Factors. 2018;36:15–40. doi: 10.1080/08977194.2018.1472089. PubMed DOI

Cheyette B.N. Ryk: Another heretical Wnt receptor defies the canon. Sci. STKE. 2004;2004:54. doi: 10.1126/stke.2632004pe54. PubMed DOI

Grunberg J.R., Hoffmann J.M., Hedjazifar S., Nerstedt A., Jenndahl L., Elvin J., Castellot J., Wei L., Moverare-Skrtic S., Ohlsson C., et al. Overexpressing the novel autocrine/endocrine adipokine WISP2 induces hyperplasia of the heart, white and brown adipose tissues and prevents insulin resistance. Sci. Rep. 2017;7:43515. doi: 10.1038/srep43515. PubMed DOI PMC

Grunberg J.R., Hammarstedt A., Hedjazifar S., Smith U. The Novel Secreted Adipokine WNT1-inducible Signaling Pathway Protein 2 (WISP2) Is a Mesenchymal Cell Activator of Canonical WNT. J. Biol. Chem. 2014;289:6899–6907. doi: 10.1074/jbc.M113.511964. PubMed DOI PMC

Davicioni E., Anderson J.R., Buckley J.D., Meyer W.H., Triche T.J. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: A report from the children’s oncology group. J. Clin. Oncol. 2010;28:1240–1246. doi: 10.1200/JCO.2008.21.1268. PubMed DOI PMC

Tang Z., Kang B., Li C., Chen T., Zhang Z. GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556–W560. doi: 10.1093/nar/gkz430. PubMed DOI PMC

Zhou L., Sheng D., Wang D., Ma W., Deng Q., Deng L., Liu S. Identification of cancer-type specific expression patterns for active aldehyde dehydrogenase (ALDH) isoforms in ALDEFLUOR assay. Cell Biol. Toxicol. 2018 doi: 10.1007/s10565-018-9444-y. PubMed DOI PMC

Levi B.P., Yilmaz O.H., Duester G., Morrison S.J. Aldehyde dehydrogenase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous systems. Blood. 2009;113:1670–1680. doi: 10.1182/blood-2008-05-156752. PubMed DOI PMC

Marcato P., Dean C.A., Pan D., Araslanova R., Gillis M., Joshi M., Helyer L., Pan L., Leidal A., Gujar S., et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells. 2011;29:32–45. doi: 10.1002/stem.563. PubMed DOI

Cho S.Y., Kang S., Kim D.S., Na H.J., Kim Y.J., Choi Y.D., Cho N.H. HSP27, ALDH6A1 and Prohibitin Act as a Trio-biomarker to Predict Survival in Late Metastatic Prostate Cancer. Anticancer Res. 2018;38:6551–6560. doi: 10.21873/anticanres.13021. PubMed DOI

Martinez-Cruzado L., Tornin J., Santos L., Rodriguez A., Garcia-Castro J., Moris F., Rodriguez R. Aldh1 Expression and Activity Increase During Tumor Evolution in Sarcoma Cancer Stem Cell Populations. Sci. Rep. 2016;6:27878. doi: 10.1038/srep27878. PubMed DOI PMC

Storer N.Y., White R.M., Uong A., Price E., Nielsen G.P., Langenau D.M., Zon L.I. Zebrafish rhabdomyosarcoma reflects the developmental stage of oncogene expression during myogenesis. Development. 2013;140:3040–3050. doi: 10.1242/dev.087858. PubMed DOI PMC

Fukada S., Ma Y., Ohtani T., Watanabe Y., Murakami S., Yamaguchi M. Isolation, characterization and molecular regulation of muscle stem cells. Front. Physiol. 2013;4:317. doi: 10.3389/fphys.2013.00317. PubMed DOI PMC

Rubin B.P., Nishijo K., Chen H.I., Yi X., Schuetze D.P., Pal R., Prajapati S.I., Abraham J., Arenkiel B.R., Chen Q.R., et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell. 2011;19:177–191. doi: 10.1016/j.ccr.2010.12.023. PubMed DOI PMC

Fukada S., Uezumi A., Ikemoto M., Masuda S., Segawa M., Tanimura N., Yamamoto H., Miyagoe-Suzuki Y., Takeda S. Molecular signature of quiescent satellite cells in adult skeletal muscle. Stem Cells. 2007;25:2448–2459. doi: 10.1634/stemcells.2007-0019. PubMed DOI

Cui S., Hano H., Harada T., Takai S., Masui F., Ushigome S. Evaluation of new monoclonal anti-MyoD1 and anti-myogenin antibodies for the diagnosis of rhabdomyosarcoma. Pathol. Int. 1999;49:62–68. doi: 10.1046/j.1440-1827.1999.00825.x. PubMed DOI

Tenente I.M., Hayes M.N., Ignatius M.S., McCarthy K., Yohe M., Sindiri S., Gryder B., Oliveira M.L., Ramakrishnan A., Tang Q., et al. Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma. Elife. 2017;6:e19214. doi: 10.7554/eLife.19214. PubMed DOI PMC

Gianakopoulos P.J., Mehta V., Voronova A., Cao Y., Yao Z., Coutu J., Wang X., Waddington M.S., Tapscott S.J., Skerjanc I.S. MyoD directly up-regulates premyogenic mesoderm factors during induction of skeletal myogenesis in stem cells. J. Biol. Chem. 2011;286:2517–2525. doi: 10.1074/jbc.M110.163709. PubMed DOI PMC

Bhattaram P., Penzo-Mendez A., Sock E., Colmenares C., Kaneko K.J., Vassilev A., Depamphilis M.L., Wegner M., Lefebvre V. Organogenesis relies on SoxC transcription factors for the survival of neural and mesenchymal progenitors. Nat. Commun. 2010;1:9. doi: 10.1038/ncomms1008. PubMed DOI PMC

Lourenco A.R., Coffer P.J. SOX4: Joining the Master Regulators of Epithelial-to-Mesenchymal Transition? Trends Cancer. 2017;3:571–582. doi: 10.1016/j.trecan.2017.06.002. PubMed DOI

Rajurkar M., Huang H., Cotton J.L., Brooks J.K., Sicklick J., McMahon A.P., Mao J. Distinct cellular origin and genetic requirement of Hedgehog-Gli in postnatal rhabdomyosarcoma genesis. Oncogene. 2014;33:5370–5378. doi: 10.1038/onc.2013.480. PubMed DOI PMC

Wang H., Garzon R., Sun H., Ladner K.J., Singh R., Dahlman J., Cheng A., Hall B.M., Qualman S.J., Chandler D.S., et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 2008;14:369–381. doi: 10.1016/j.ccr.2008.10.006. PubMed DOI PMC

Shibue T., Weinberg R.A. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 2017;14:611–629. doi: 10.1038/nrclinonc.2017.44. PubMed DOI PMC

Dongre A., Weinberg R.A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 2018;20:69–84. doi: 10.1038/s41580-018-0080-4. PubMed DOI

Jolly M.K., Somarelli J.A., Sheth M., Biddle A., Tripathi S.C., Armstrong A.J., Hanash S.M., Bapat S.A., Rangarajan A., Levine H. Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. Pharmacol. Ther. 2018;194:161–184. doi: 10.1016/j.pharmthera.2018.09.007. PubMed DOI

Jolly M.K., Jia D., Boareto M., Mani S.A., Pienta K.J., Ben-Jacob E., Levine H. Coupling the modules of EMT and stemness: A tunable stemness window model. Oncotarget. 2015;6:25161–25174. doi: 10.18632/oncotarget.4629. PubMed DOI PMC

Bierie B., Pierce S.E., Kroeger C., Stover D.G., Pattabiraman D.R., Thiru P., Liu Donaher J., Reinhardt F., Chaffer C.L., Keckesova Z., et al. Integrin-beta4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. Proc. Natl. Acad. Sci. USA. 2017;114:E2337–E2346. doi: 10.1073/pnas.1618298114. PubMed DOI PMC

Yang J., Du X., Wang G., Sun Y., Chen K., Zhu X., Lazar A.J., Hunt K.K., Pollock R.E., Zhang W. Mesenchymal to epithelial transition in sarcomas. Eur. J. Cancer. 2014;50:593–601. doi: 10.1016/j.ejca.2013.11.006. PubMed DOI

Sannino G., Marchetto A., Kirchner T., Grunewald T.G.P. Epithelial-to-Mesenchymal and Mesenchymal-to-Epithelial Transition in Mesenchymal Tumors: A Paradox in Sarcomas? Cancer Res. 2017;77:4556–4561. doi: 10.1158/0008-5472.CAN-17-0032. PubMed DOI

Kahlert U.D., Joseph J.V., Kruyt F.A.E. EMT- and MET-related processes in nonepithelial tumors: Importance for disease progression, prognosis, and therapeutic opportunities. Mol. Oncol. 2017;11:860–877. doi: 10.1002/1878-0261.12085. PubMed DOI PMC

Wiggan O., Fadel M.P., Hamel P.A. Pax3 induces cell aggregation and regulates phenotypic mesenchymal-epithelial interconversion. J. Cell Sci. 2002;115:517–529. PubMed

Li R., Liang J., Ni S., Zhou T., Qing X., Li H., He W., Chen J., Li F., Zhuang Q., et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell. 2010;7:51–63. doi: 10.1016/j.stem.2010.04.014. PubMed DOI

Hoffding M.K., Hyttel P. Ultrastructural visualization of the Mesenchymal-to-Epithelial Transition during reprogramming of human fibroblasts to induced pluripotent stem cells. Stem Cell Res. 2015;14:39–53. doi: 10.1016/j.scr.2014.11.003. PubMed DOI

Kashima T., Kawaguchi J., Takeshita S., Kuroda M., Takanashi M., Horiuchi H., Imamura T., Ishikawa Y., Ishida T., Mori S., et al. Anomalous cadherin expression in osteosarcoma. Possible relationships to metastasis and morphogenesis. Am. J. Pathol. 1999;155:1549–1555. doi: 10.1016/S0002-9440(10)65471-5. PubMed DOI PMC

Kashima T., Nakamura K., Kawaguchi J., Takanashi M., Ishida T., Aburatani H., Kudo A., Fukayama M., Grigoriadis A.E. Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int. J. Cancer. 2003;104:147–154. doi: 10.1002/ijc.10931. PubMed DOI

Camand E., Peglion F., Osmani N., Sanson M., Etienne-Manneville S. N-cadherin expression level modulates integrin-mediated polarity and strongly impacts on the speed and directionality of glial cell migration. J. Cell Sci. 2012;125:844–857. doi: 10.1242/jcs.087668. PubMed DOI

Lammens T., Swerts K., Derycke L., De Craemer A., De Brouwer S., De Preter K., Van Roy N., Vandesompele J., Speleman F., Philippe J., et al. N-cadherin in neuroblastoma disease: Expression and clinical significance. PLoS ONE. 2012;7:e31206. doi: 10.1371/journal.pone.0031206. PubMed DOI PMC

Nakagawa S., Takeichi M. Neural crest emigration from the neural tube depends on regulated cadherin expression. Development. 1998;125:2963–2971. PubMed

Blindt R., Bosserhoff A.K., Dammers J., Krott N., Demircan L., Hoffmann R., Hanrath P., Weber C., Vogt F. Downregulation of N-cadherin in the neointima stimulates migration of smooth muscle cells by RhoA deactivation. Cardiovasc. Res. 2004;62:212–222. doi: 10.1016/j.cardiores.2004.01.004. PubMed DOI

Tiwari N., Tiwari V.K., Waldmeier L., Balwierz P.J., Arnold P., Pachkov M., Meyer-Schaller N., Schubeler D., van Nimwegen E., Christofori G. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell. 2013;23:768–783. doi: 10.1016/j.ccr.2013.04.020. PubMed DOI

Preussner J., Zhong J., Sreenivasan K., Gunther S., Engleitner T., Kunne C., Glatzel M., Rad R., Looso M., Braun T., et al. Oncogenic Amplification of Zygotic Dux Factors in Regenerating p53-Deficient Muscle Stem Cells Defines a Molecular Cancer Subtype. Cell Stem Cell. 2018;23:794–805. doi: 10.1016/j.stem.2018.10.011. PubMed DOI

Mochizuki Y., Furukawa K. Application of coomassie brilliant blue staining to cultured hepatocytes. Cell Biol. Int. Rep. 1987;11:367–371. doi: 10.1016/0309-1651(87)90003-8. PubMed DOI

Mikulenkova E., Neradil J., Zitterbart K., Sterba J., Veselska R. Overexpression of the Np73 isoform is associated with centrosome amplification in brain tumor cell lines. Tumor Biol. 2015;36:7483–7491. doi: 10.1007/s13277-015-3474-3. PubMed DOI

Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B., et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods. 2012;9:676–682. doi: 10.1038/nmeth.2019. PubMed DOI PMC

Skoda J., Neradil J., Zitterbart K., Sterba J., Veselska R. EGFR signaling in the HGG-02 glioblastoma cell line with an unusual loss of EGFR gene copy. Oncol. Rep. 2014;31:480–487. doi: 10.3892/or.2013.2864. PubMed DOI

Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009;4:44–57. doi: 10.1038/nprot.2008.211. PubMed DOI

Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma